News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
706,572 Results
Type
Article (41015)
Company Profile (275)
Press Release (665282)
Multimedia
Podcasts (56)
Webinars (12)
Section
Business (206376)
Career Advice (2011)
Deals (35740)
Drug Delivery (97)
Drug Development (82382)
Employer Resources (172)
FDA (16340)
Job Trends (15011)
News (349090)
Policy (32797)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2594)
Accelerated approval (5)
Adcomms (23)
Allergies (85)
Alliances (50237)
ALS (89)
Alzheimer's disease (1383)
Antibody-drug conjugate (ADC) (141)
Approvals (16342)
Artificial intelligence (263)
Autoimmune disease (22)
Automation (16)
Bankruptcy (361)
Best Places to Work (11773)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (199)
Bladder cancer (82)
Brain cancer (29)
Breast cancer (286)
Cancer (2343)
Cardiovascular disease (173)
Career advice (1680)
Career pathing (30)
CAR-T (158)
Cell therapy (437)
Cervical cancer (20)
Clinical research (67044)
Collaboration (853)
Compensation (530)
Complete response letters (20)
COVID-19 (2601)
CRISPR (41)
C-suite (248)
Cystic fibrosis (100)
Data (2212)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6444)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (87143)
Editorial (38)
Employer branding (21)
Employer resources (146)
Events (114269)
Executive appointments (731)
FDA (17598)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (753)
Gene editing (106)
Generative AI (23)
Gene therapy (304)
GLP-1 (716)
Government (4444)
Grass and pollen (4)
Guidances (59)
Healthcare (19054)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (121)
Indications (29)
Infectious disease (2744)
Inflammatory bowel disease (138)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (97)
Interviews (311)
IPO (16637)
IRA (41)
Job creations (3657)
Job search strategy (1426)
Kidney cancer (11)
Labor market (38)
Layoffs (485)
Leadership (17)
Legal (7939)
Liver cancer (78)
Lung cancer (337)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (305)
MASH (66)
Medical device (13426)
Medtech (13431)
Mergers & acquisitions (19648)
Metabolic disorders (685)
Multiple sclerosis (81)
NASH (16)
Neurodegenerative disease (89)
Neuropsychiatric disorders (27)
Neuroscience (1919)
NextGen: Class of 2025 (6578)
Non-profit (4515)
Northern California (2679)
Now hiring (39)
Obesity (365)
Opinion (210)
Ovarian cancer (77)
Pain (85)
Pancreatic cancer (84)
Parkinson's disease (149)
Partnered (21)
Patents (235)
Patient recruitment (112)
Peanut (46)
People (57998)
Pharmaceutical (67)
Pharmacy benefit managers (18)
Phase I (20948)
Phase II (29505)
Phase III (22010)
Pipeline (1194)
Policy (139)
Postmarket research (2594)
Preclinical (8874)
Press Release (64)
Prostate cancer (111)
Psychedelics (31)
Radiopharmaceuticals (258)
Rare diseases (380)
Real estate (5967)
Recruiting (65)
Regulatory (22497)
Reports (46)
Research institute (2370)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (132)
Series B (85)
Service/supplier (11)
Sickle cell disease (53)
Southern California (2298)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3641)
State (2)
Stomach cancer (15)
Supply chain (68)
Tariffs (39)
The Weekly (36)
United States (23218)
Vaccines (695)
Venture capitalists (41)
Weight loss (237)
Women's health (35)
Worklife (16)
Date
Today (163)
Last 7 days (885)
Last 30 days (2663)
Last 365 days (33266)
2025 (10718)
2024 (35676)
2023 (40498)
2022 (51695)
2021 (56233)
2020 (54539)
2019 (47056)
2018 (35455)
2017 (32657)
2016 (32028)
2015 (38065)
2014 (31750)
2013 (26719)
2012 (28926)
2011 (29660)
2010 (27611)
Location
Africa (727)
Alabama (58)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (38592)
Australia (6312)
California (6139)
Canada (2012)
China (531)
Colorado (265)
Connecticut (273)
Delaware (146)
Europe (83897)
Florida (907)
Georgia (206)
Idaho (58)
Illinois (542)
India (25)
Indiana (307)
Iowa (11)
Japan (164)
Kansas (105)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (897)
Massachusetts (4645)
Michigan (219)
Minnesota (394)
Mississippi (2)
Missouri (81)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1727)
New Mexico (28)
New York (1744)
North Carolina (972)
North Dakota (8)
Northern California (2679)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1381)
Puerto Rico (12)
Rhode Island (33)
South America (1108)
South Carolina (22)
South Dakota (1)
Southern California (2298)
Tennessee (102)
Texas (909)
Utah (180)
Virginia (144)
Washington D.C. (62)
Washington State (553)
West Virginia (3)
Wisconsin (54)
706,572 Results for "aktis oncology inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AKTIS ONCOLOGY TO PARTICIPATE IN THE 45th ANNUAL TD COWEN HEALTH CARE CONFERENCE
February 25, 2025
·
1 min read
Press Releases
Aktis Oncology Appoints Biotech Industry Veteran Mary Thistle to its Board of Directors
February 4, 2025
·
3 min read
Press Releases
AKTIS ONCOLOGY TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
January 10, 2025
·
1 min read
Business
AKTIS ONCOLOGY NAMES TYLER BENEDUM, Ph.D., CHIEF TECHNICAL OFFICER
Aktis Oncology today announced the promotion of Tyler Benedum, Ph.D., to Chief Technical Officer, effective immediately.
May 30, 2024
·
3 min read
Business
Aktis Oncology Enters Into Strategic Collaboration With Lilly to Discover and Develop Novel Anticancer Radiopharmaceuticals
Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, announced a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform.
May 21, 2024
·
3 min read
Business
Lilly Inks Potential $1.1B Radiopharma Deal with Aktis Oncology
Eli Lilly is paying $60 million upfront to Aktis Oncology to discover and develop novel tumor-targeting radiopharmaceuticals, as radiopharma dealmaking continues to heat up in 2024.
May 21, 2024
·
2 min read
·
Kate Goodwin
Business
Aktis Oncology Expands its Board of Directors with Appointment of Nuclear Medicine Expert Ken Herrmann, MD, MBA
Aktis Oncology, a clinical-stage biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the appointment of Ken Herrmann, MD, MBA, to the Company’s Board of Directors.
June 13, 2024
·
3 min read
Genetown
Aktis Oncology to Participate in the 2024 Guggenheim Healthcare Talks Radiopharmaceuticals Day
Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced that Matthew Roden, Ph.D., President and Chief Executive Officer, will be presenting at the 2024 Guggenheim Healthcare Talks Radiopharmaceuticals Day, being held Monday, May 13, 2024, in New York City.
May 9, 2024
·
1 min read
Genetown
Aktis Oncology Announces Presentation at the Oligonucleotide & Peptide Therapeutics (TIDES USA) Conference 2024
Aktis Oncology, a biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announces an oral presentation at the Oligonucleotide & Peptide Therapeutics Conference 2024, being held May 14-17, 2024, in Boston, Mass. and virtually.
May 13, 2024
·
1 min read
Genetown
Aktis Oncology to Participate in TD Cowen’s 2nd Annual Radiopharmaceutical Innovation Summit
Aktis Oncology, a clinical biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced that Matthew Roden, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on Monday, June 17, 2024 at 9:20 a.m. ET.
June 10, 2024
·
1 min read
1 of 70,658
Next
